A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
A legfontosabb adatok
- Ki végzi
- Chiesi Farmaceutici S.p.A.
- Hol
- Japán6 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 6 fő, tervezett
- Kezdés
- 2025. ápr. 18.
- Várható befejezés
- 2029. szept.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Oleogel-S10
- A regiszteradat frissítve
- 2025. december 22.
Ki vehet részt
- Életkor
- 21 nap felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female aged ≥ 21 days
- Confirmed diagnosis of either JEB or DEB
- Both biological parents and all 4 grandparents of Japanese descent
- At least 3 EB wounds that meet the following criteria at the time of enrollment:; All are located outside of the anogenital region; All are distinguishable from any other wounds on the subject's body (separated by a minimum of 5 cm); At least one has been present for a minimum of 21 days but less than 9 months AND is 10 cm2 to 50 cm2 in size; At least two have been present for a minimum of 21 days but less than 9 months AND/OR are 10 cm2 to 50 cm2 in size
- A female subject must meet one of the following criteria:; If of childbearing potential, she must:; Have a negative pregnancy test result at Screening and Baseline Visits, AND; Agree to use one of the following highly reliable methods of contraception from the day of the informed consent signature until the day after the last Oleogel- S10 application. The following methods are acceptable:; Placement of an intrauterine device (IUD) or intrauterine releasing system (IUS); Combined (both estrogen and progestogen) hormonal contraception (oral) associated with inhibition of ovulation, supplemented with a barrier method (preferably male condom); Bilateral tubal occlusion; Sexual abstinence, defined as refraining from heterosexual intercourse during the entire study period; Partner vasectomy, provided that the partner is the sole sexual partner and has received medical verification of the surgical success; Be of non-childbearing potential, defined as one of the following:; Pre-menarche, OR; Post-menopausal (12 consecutive months of amenorrhea without an alternative medical cause), OR; Permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy (supporting evidence required)
- Subject and/or subject's legal representative has been informed about the study, has read and understood the information provided, and has given written informed consent
- Subject and/or subject's legal representative is able and willing to follow all study procedures and instructions
Ki nem vehet részt
- Receipt of systemic antibiotics for wound-related infections within 7 days prior to enrollment
- Receipt of systemic or topical (on EB wounds) steroids within 30 days prior to enrollment Exceptions: Inhaled, ophthalmic, or mucosal applications, such as budesonide suspension for esophageal strictures
- Receipt of immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrollment Note: Dupilumab to manage pruritis is allowed if the subject has been on a stable dose for more than 3 months prior to baseline
- Receipt of systemic gene therapy for the treatment of inherited EB
- Receipt of short-acting stem cell therapy (infusion of Muse cells, allogeneic adipocyte-derived MSC sheet (topically applied), TEMCELL (allogeneic MSCs, subcutaneous injection)) within 6 months prior to study enrollment
- Receipt of topical gene therapy for the treatment of inherited EB (e.g., beremagene geperpavec) within 3 months prior to enrollment
- Enrollment in any other interventional study or treated with any other investigational drug for any disease within 4 weeks prior to enrollment
- Hypersensitivity to Oleogel-S10 or any of its excipients
- Current and/or former malignancy, including skin malignancies such as basal cell carcinoma and squamous cell carcinoma
- Diagnosis of EB subtypes simplex or Kindler EB
- Receipt of a JACE® skin graft on any of the target wounds
- Females: Pregnant or lactating, or of childbearing potential with a fertile male partner and unwilling to use a highly reliable method of contraception from the informed consent signature until study participation ends
- Presence of any factor in the subject and/or legal representative that could interfere with study compliance, such as the ability to attend the scheduled study visits or to properly manage the dressing changes at home
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn if Oleogel-S10 gel works to treat skin wounds from two types of inherited epidermolysis bullosa (EB): junctional EB (JEB) or dystrophic EB (DEB) in the Japanese population. Children and adults may participate. The trial also looks at the safety of Oleogel-S10 gel. The main questions it will answer are:
A teljes eredeti leírásKevesebb
* Does Oleogel-S10 gel close wounds from JEB or DEB within 45 days or reduce the size of the wounds? * Are there any medical problems when using Oleogel-S10 gel? * How much of the drug ends up in your blood?
The study has 2 parts. In Part 1, participants will:
* Apply Oleogel-S10 gel to the EB wound dressings at least once every 4 days for 45 days. * Visit the clinic once every 2 weeks for checkups and tests. If participants complete Part 1, they may participate in Part 2 if they choose to. In Part 2, participants will continue to receive Oleogel-S10 gel until the product is available to buy in Japan or until the trial is stopped by the company.
A vizsgálat csoportja
- Oleogel-S10A vizsgált kezelés
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Multi-centeR, Open-label Study to EValuate the Safety, Efficacy, and Pharmacokinetics of FIlsuVEz (Oleogel-S10) in Japanese Subjects With Epidermolysis Bullosa (REVIVE)
- A regiszteradat frissítve
- 2025. december 22.